Atria Investments Inc Trims Holdings in Insulet Co. (NASDAQ:PODD)

Atria Investments Inc reduced its stake in shares of Insulet Co. (NASDAQ:PODD) by 5.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,533 shares of the medical instruments supplier’s stock after selling 330 shares during the quarter. Atria Investments Inc’s holdings in Insulet were worth $1,288,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. ABLE Financial Group LLC purchased a new position in Insulet during the third quarter valued at approximately $952,000. Portside Wealth Group LLC purchased a new position in Insulet during the third quarter valued at approximately $205,000. Principal Financial Group Inc. raised its position in Insulet by 4.0% during the third quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier’s stock valued at $20,065,000 after acquiring an additional 3,355 shares in the last quarter. WoodTrust Financial Corp raised its position in Insulet by 57.7% during the third quarter. WoodTrust Financial Corp now owns 2,365 shares of the medical instruments supplier’s stock valued at $551,000 after acquiring an additional 865 shares in the last quarter. Finally, Graypoint LLC purchased a new position in Insulet during the third quarter valued at approximately $206,000.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $260.12 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business’s 50 day moving average price is $237.77 and its 200-day moving average price is $207.72. The firm has a market capitalization of $18.25 billion, a PE ratio of 44.54, a P/E/G ratio of 4.11 and a beta of 1.22. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.40.

Analysts Set New Price Targets

PODD has been the subject of several recent research reports. Canaccord Genuity Group lifted their price target on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Morgan Stanley boosted their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Sanford C. Bernstein started coverage on Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. Piper Sandler boosted their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, Citigroup boosted their price objective on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.